APLI:CC News and Press, Appili Therapeutics Inc. From 04/02/24

Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and resources to advance key programs NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED S...

HALIFAX, Nova Scotia, March 12, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced a publicat...

FDA approved LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL Additional USAFA funding commitment from the U.S. Air Force Academy, intended to advance the ATI-1701 program toward an IND submission to the FDA Engaging regulatory authorities to align on ATI-18...

Synex Renewable Energy Corporation (SXI:CA) is expected to report for Q2 2024 Dye & Durham Limited (DND:CA) is expected to report for Q2 2024 Economic Investment Trust Limited (EVT:CA) is expected to report for quarter end 2023-12-31 Western Forest Products Inc. (WEF:CA) is expect...

Patent coverage provides drug market exclusivity through at least 2039 Pre-IND meeting with the FDA granted to discuss ATI-1701’s regulatory, CMC, toxicology, and Phase 1 strategies Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “...

FDA approves ATI-1501 for Metronidazole Oral Suspension 500mg/5mL and its brand name LIKMEZ™ Appili received an additional funding commitment from the U.S. Air Force Academy for ATI-1701, bringing the total program funding awarded to US$14 million Appili Therapeutics Appoin...

K-Bro Linen Inc. (KBL:CA) is expected to report $0.57 for Q3 2023 Yellow Pages Limited (Y:CA) is expected to report for Q3 2023 Ascot Resources Ltd. (AOT:CA) is expected to report for Q3 2023 Park Lawn Corporation (PLC:CA) is expected to report $0.27 for Q3 2023 Hut 8 Mining Corp....

Appili Therapeutics Inc. (APLI:CA) is expected to report $-0.02 for Q2 2024

Additional US$6.6 million funding commitment for ATI-1701 brings the total program funding awarded to approximately US$14 million These funds along with other potential funding sources, are anticipated to continue to advance the ATI-1701 program toward an IND submission to the FDA in 2024...

Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the results from its annual meeting of shareholders held earlier today. ...